Sierra Oncology, Inc. (SRRA) News & Overview - Discounting Cash Flows
SRRA
Sierra Oncology, Inc.
SRRA (NASDAQ)

SRRA's Business Model

Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
Sector & Industry Healthcare / Biotechnology
Website https://www.sierraoncology.com
CEO (Chief Executive Officer) Nicholas Glover
Number of Employees
IPO date July 16, 2015

SRRA Latest News

Contact
CountryCA
Address2150 ? 885 West Georgia Street
CityVancouver
StateBC
Phone16045586536
Zip Code94404
Other Identifiers
CIK0001290149
ISINUS82640U4040
CUSIP82640U404
Open54.98
Previous Close54.99
Volume0
Average Volume651.5 Thou.
Day’s Range54.98 – 55.01
52 Week Range54.98-55.01
MA (50)54.7342
MA (200)33.6943
Market Cap0
Shares Out.0
Earnings DateAug 04, 2022
Beta
Last Dividend
EPS
PE

Industry Competitors for SRRA

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us